MedPath
HSA Approval

PODOXRED POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 500MG

SIN15817P

PODOXRED POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 500MG

PODOXRED POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 500MG

September 23, 2019

ZYFAS PHARMA PTE LTD

ZYFAS PHARMA PTE LTD

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantZYFAS PHARMA PTE LTD
Licence HolderZYFAS PHARMA PTE LTD

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

INJECTION, POWDER, FOR SOLUTION

PARENTERAL

Medical Information

L01BA04

pemetrexed

Manufacturer Information

ZYFAS PHARMA PTE. LTD.

DR.REDDY'S LABORATORIES LTD

Active Ingredients

Pemetrexed disodium(Amorphous) 551.4 mg eqv to Pemetrexed

500 mg

Pemetrexed

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

PODOXRED POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 500MG - HSA Approval | MedPath